Course Title: CE 03: Toward a Precision Medicine of Alzheimer's Disease: Cognitive Phenotypes in the era of Genomics, Neuroimaging and Fluid Biomarkers (Saykin)

Credit Hours: 3

Instructor(s) Andy Saykin

Andrew Saykin, PsyD, ABCN
Raymond C. Beeler Professor of Radiology and Imaging Sciences at the Indiana University School of Medicine

CE Workshop # 3:

Toward a Precision Medicine of Alzheimer’s Disease: Cognitive Phenotypes in the era of Genomics, Neuroimaging and Fluid Biomarkers

Abstract & Learning Objectives:
This workshop will provide an update on research in Alzheimer’s disease (AD) including the NIA-Alzheimer’s Association research framework that emphasizes biomarker-based classification and staging. Topics will include recent developments in candidate genes and polygenic risk scores, structural, functional and molecular neuroimaging, and CSF and blood-based fluid biomarkers, as well as other emerging methods. Systems biology-oriented research consortia are providing unprecedented large scale data sets on AD and related disorders for analysis by the scientific community. Cognitive phenotypes, longitudinal profiles and stages including subjective cognitive decline (SCD), mild cognitive impairment (MCI) and AD dementia are being revisited against this background. Nearly all normative data for cognitive tests in older adults was collected before AD biomarkers became widely available which may have important implications for assessment and interpretation. Progress in genetic testing and biomarkers and the explosive development of large-scale multi-omics data leads to new clinical questions and ethical challenges. What biomarker results should be returned to a patient who is symptomatic? What about to an asymptomatic individual? An important consideration is whether findings are currently actionable. In the future, we can expect precision healthcare of cognitive aging to offer an expanded array of targeted interventions based on personalized analysis of clinical, biological, and environmental/lifestyle factors. These developments create challenges and opportunities. Upon conclusion of this course, learners will be able to:
  • Identify some of the “top twenty” Alzheimer’s candidate genes and their pathways
  • Describe the current status of A/T/N/V biomarkers for Alzheimer’s disease
  • Discuss the role of cognitive phenotypes in relation to biomarker status
  • Explain the development and use of polygenic risk scores
  • Assess ethical issues related to return of genetic and biomarker results

Speaker Biography:
Dr. Andrew Saykin, PsyD, ABCN, is the Raymond C. Beeler Professor of Radiology and Imaging Sciences at the Indiana University School of Medicine where he also holds appointments as Professor of Medical and Molecular Genetics, Neurology and Psychiatry. He joined Indiana University as director of the IU Center for Neuroimaging in late 2006, having previously served on the faculty at Dartmouth Medical School and the University of Pennsylvania. In 2013, he was appointed as director of the NIA-designated Indiana Alzheimer Disease Center. Nationally, he serves on the Executive Committee of the NIA AD Centers Program and has led the Genetics Core of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) since its inception. Dr. Saykin’s expertise is in the areas of cognitive neuroscience, multimodal neuroimaging and human genetics. His research has been funded by the NIA, NINDS, NCI, NIBIB, and NSF. His current research program is focused on integrating multimodal brain imaging, biomarker and genomic data to enhance the understanding of disorders affecting memory in older adults with a special focus on relationship among brain, gene and protein/metabolite networks. Dr. Saykin serves as the founding Editor-in-Chief (since 2006) of Brain Imaging and Behavior, a Springer-Nature journal, and is also active in training of the next generation of clinical and translational researchers including numerous pre- and post-doctoral scientists.